

## **IN THE CLAIMS**

This listing of claims below will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1. (currently amended): A method for ~~detecting~~ ~~diagnosing~~ cancer, said method comprising detecting a soluble GPC3 protein level in a test sample, and determining whether said detected soluble GPC3 level is greater than a normal control ~~basal~~ level of GPC3.
2. (currently amended): The method ~~for diagnosing cancer~~ of claim 1, wherein the soluble GPC3 protein is a N-terminal peptide of GPC3.
3. (currently amended): The method ~~for diagnosing cancer~~ of claim 2, wherein the N-terminal peptide of GPC3 is a peptide fragment consisting of the amino acid sequence from the 1st amino acid to the 358th amino acid of SEQ ID NO: 4 ~~having the amino acid sequence of GPC3 consisting of the 1st amino acid to the 358th amino acid.~~
4. (currently amended): The ~~diagnosis~~ method of claim 1, wherein the test sample is selected from the group consisting of blood, serum and plasma.
5. (currently amended): The ~~diagnosis~~ method of claim 1, wherein the cancer is hepatic cancer.
6. (previously presented): The method of claim 1, comprising using an anti-GPC3 antibody.
7. (original): The method of claim 6, comprising using an anti-GPC3 antibody immobilized on a carrier and an anti-GPC3 antibody labeled with a labeling substances.
8. (original): The method of claim 7, wherein the labeling substances are biotin.

9-14. (canceled)

15. (currently amended): The ~~diagnosis~~ method of claim 3, wherein the test sample is selected from the group consisting of blood, serum and plasma.

16. (currently amended): The ~~diagnosis~~ method of claim 3, wherein the cancer is hepatic cancer.

17. (currently amended): The ~~diagnosis~~ method of claim 4, wherein the cancer is hepatic cancer.

18. (previously presented): The method of claim 3, comprising using an anti-GPC3 antibody.

19-20. (canceled)